Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
Author
dc.contributor.author
Renner, Alex
Author
dc.contributor.author
Burotto, Mauricio
Author
dc.contributor.author
Valdés, José Miguel
Author
dc.contributor.author
Román Sobarzo, Juan Carlos
Author
dc.contributor.author
Walton Díaz, Annerleim Nylsello
Admission date
dc.date.accessioned
2021-12-02T13:44:42Z
Available date
dc.date.available
2021-12-02T13:44:42Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Ther Adv Urol 2021, Vol. 13: 1–7
es_ES
Identifier
dc.identifier.other
10.1177/17562872211029779
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/183010
Abstract
dc.description.abstract
Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown
activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI
agents in the first- and second-line settings. This has led to an increased interest in studying
their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant
unmet need. This non-systematic review will look at the evidence supporting the use of ICI
in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and
possible future applications for these drugs.
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
SAGE
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States